MRI heralds secondary nigral lesion after brain ischemia in mice: A secondary time window for neuroprotection

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 12, 2015, Pages 1903-1909

  Prinz, Vincent ^a   Hetzer, Anna Maria ^a   Müller, Susanne ^a   Balkaya, Mustafa ^a   Leithner, Christoph ^a   Kronenberg, Golo ^a   Endres, Matthias ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

dopamine; experimental; focal ischemia; immunohistochemistry; MRI; neurodegeneration

Indexed keywords

DIZOCILPINE; TACROLIMUS; DIZOCILPINE MALEATE; IMMUNOSUPPRESSIVE AGENT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CELL LOSS; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; EXOFOCAL POSTISCHEMIC NEURONAL DEGENERATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION; SUBSTANTIA NIGRA; WILD TYPE; 129 MOUSE; ANIMAL; CELL COUNT; INFARCTION, MIDDLE CEREBRAL ARTERY; NERVE DEGENERATION; PATHOLOGY;

ANIMALS; BRAIN ISCHEMIA; CELL COUNT; DIZOCILPINE MALEATE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, 129 STRAIN; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; SUBSTANTIA NIGRA; TACROLIMUS;

EID: 84948720018     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.153     Document Type: Article

References (23)

1. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011; 76: S85-S90.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22: 391-397.
3. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010; 67: 181-198.
4. Prinz V, Endres M. Statins and stroke: prevention and beyond. Curr Opin Neurol. 2011; 24: 75-80.
5. Zhao F, Kuroiwa T, Miyasaka N, Nagaoka T, Nakane M, Tamura A, et al. Characteristic changes in T(2)-value, apparent diffusion coefficient, and ultrastructure of substantia nigra evolving exofocal postischemic neuronal death in rats. Brain Res. 2001; 895: 238-244.
6. Kronenberg G, Balkaya M, Prinz V, Gertz K, Ji S, Kirste I, et al. Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol Psychiatry. 2012; 72: 273-281.
7. Zhang J, Zhang Y, Xing S, Liang Z, Zeng J. Secondary neurodegeneration in remote regions after focal cerebral infarction: a new target for stroke management?. Stroke. 2012; 43: 1700-1705.
8. Rodriguez-Grande B, Blackabey V, Gittens B, Pinteaux E, Denes A. Loss of substance P and inflammation precede delayed neurodegeneration in the substantia nigra after cerebral ischemia. Brain Behav Immun. 2013; 29: 51-61.
9. Baron J-C, Yamauchi H, Fujioka M, Endres M. Selective neuronal loss in ischemic stroke and cerebrovascular disease. J Cereb Blood Flow Metab. 2014; 34: 2-18.
10. Macleod MR, O'Collins T, Horky LL, Howell DW, Donnan GA. Systematic review and meta-Analysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005; 25: 713-721.
11. Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008; 39: 433-438.
12. Engel O, Kolodziej S, Dirnagl U, Prinz V. Modeling stroke in mice - middle cerebral artery occlusion with the filament model. J Vis Exp. 2011; 10.3791/2423.
13. Soriano MA, Justicia C, Ferrer I, Rodríguez-Farré E, Planas AM. Striatal infarction in the rat causes a transient reduction of tyrosine hydroxylase immunoreactivity in the ipsilateral substantia nigra. Neurobiol Dis. 1997; 4: 376-385.
14. Yamada K, Goto S, Yoshikawa M, Ushio Y. Gabaergic transmission and tyrosine hydroxylase expression in the nigral dopaminergic neurons: an in vivo study using a reversible ischemia model of rats. Neuroscience. 1996; 73: 783-789.
15. Winter B, Juckel G, Viktorov I, Katchanov J, Gietz A, Sohr R, et al. Anxious and hyperactive phenotype following brief ischemic episodes in mice. Biol Psychiatry. 2005; 57: 1166-1175.
16. Zhao F, Kuroiwa T, Miyasaka N, Nagaoka T, Nakane M, Tamura A, et al. Ultrastructural and MRI study of the substantia nigra evolving exofocal post-ischemic neuronal death in the rat. Neuropathology. 2002; 22: 91-105.
17. Nakane M, Teraoka A, Asato R, Tamura A. Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke. 1992; 23: 328-332.
18. Ogawa T, Okudera T, Inugami A, Noguchi K, Kado H, Yoshida Y, et al. Degeneration of the ipsilateral substantia nigra after striatal infarction: evaluation with MR imaging. Radiology. 1997; 204: 847-851.
19. Kinoshita T, Moritani T, Shrier DA, Wang HZ, Hiwatashi A, Numaguchi Y, et al. Secondary degeneration of the substantia nigra and corticospinal tract after hemorrhagic middle cerebral artery infarction: diffusion-weighted MR findings. Magn Reson Med Sci. 2002; 1: 175-178.
20. Becker C, Jick SS, Meier CR. Risk of stroke in patients with idiopathic Parkinson disease. Parkinsonism Relat Disord. 2010; 16: 31-35.
21. Kronenberg G, Gertz K, Heinz A, Endres M. Of mice and men: modelling poststroke depression experimentally. Br J Pharmacol. 2014; 171: 4673-4689.
22. Perrin S. Preclinical research: Make mouse studies work. Nature. 2014; 507: 423-425.
23. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59: 1151-1159.